Omalizumab in the Treatment of Chronic Urticaria during Pregnancy

Chronic urticaria during pregnancy represents a prevalent dermatological condition, with some patients experiencing severe symptoms including intense pruritus, sleep disturbances, and potentially life-threatening manifestations. However, due to the unique physiological state of pregnancy, treatment options are significantly constrained. Conventional antihistamine therapy remains the primary pharmacological approach, yet exhibits suboptimal efficacy in certain cases. Prolonged glucocorticoid administration may elevate risks of gestational hypertension and preterm delivery. Omalizumab, a humanized monoclonal antibody targeting immunoglobulin E (IgE), has emerged in recent years as a potential therapeutic alternative for refractory chronic urticaria in pregnant populations. This article reviews the relevant studies on the treatment of chronic urticaria during pregnancy with omalizumab, elaborates the mechanism of action of omalizumab, analyzes the treatment needs and traditional treatment methods of chronic urticaria during pregnancy, explores the treatment of chronic urticaria during pregnancy with omalizumab, and compares the differences in safety and effectiveness between omalizumab and traditional treatments, so as to provide reference for clinical treatment.